STAT2d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
bovnews1d
Wells Fargo Issues Overweight Rating for Exact Sciences Corp (EXAS) Stock
Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...
FiercePharma5d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign ...
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
Yahoo Finance2h
EXAS Jan 2026 22.500 call
MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
The Battle Brewing Over Blood Tests for Cancer
Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...